In a study of ctDNA in nTFHL-AI by Zhang et al., RHOA G17 codon mutations were significantly associated with genes involved in “PD-L1 expression and PD-1 checkpoint pathway in cancer” by pathway analysis, suggesting that patients harboring such mutations may respond more favorably to checkpoint inhibition [271]. This evidence concerns the gene RHOA and cancer.